Oxford Nanopore Technologies plc (ONT.L)
LSE · GBp · Healthcare · Biotechnology
£215.00 (+2.19%) as of
Key statistics
- Market cap
- 2.10B
- Forward P/E
- -29.69
- EPS (TTM)
- -0.12
- Dividend yield
- 0.00%
- 52-week range
- 95.61 – 238.80
- Beta
- 0.87
- Revenue (TTM)
- 235M
- Profit margin
- -51.66%
- Analyst target
- £209.82
- Volume
- 1.06M
About Oxford Nanopore Technologies plc
Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows analysis of DNA or RNA. The company offers MinION Mk 1D, a portable device for DNA and RNA sequencing; and GridION and GridION Q, a compact bench top device that delivers a version of hardware, software, and chemistry. It also provides PromethION products, such as PromethION 2, PromethION 24, and PromethION 48. The company has a collaboration with Cepheid to develop and commercialize automated infectious disease sequencing solutions. It operates in the region of Americas, Europe, the Middle East, Africa, India, and the Asia Pacific. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies plc in May 2008. Oxford Nanopore Technologies plc was incorporated in 2005 and is headquartered in Oxford, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Oxford, United Kingdom
- Employees
- 1,314
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.